Press Releases
Date picker
Category
Results per page
Intellect Neurosciences and iNovacia Enter into a Research Service Agreement
NEW YORK and STOCKHOLM, Oct. 04, 2012 - Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of proteinopathies,…
Interim Report for Kancera AB (publ) Q2 2012
Regulatory
All figures relate to the Kancera Group unless otherwise specified. The 2011 comparison figures for operating income and income after financial items were affected by the release of negative goodwill…
Kancera strengthens patent rights related to ROR antibody therapy
Kancera announces that it has signed an agreement with Bioinvent to acquire BioInvent ́s rights to the patent application WO 2011/079902, covering therapeutic antibodies directed against the ROR receptor for…
Kancera to present at the 2012 BIO International Convention
Kancera AB today announced that Dr. Thomas Olin, CEO of Kancera, will present the company at the 2012 BIO International Convention taking place June 18-21 in Boston, USA.
Professor Carl-Henrik Heldin strengthens the Board of Kancera
Kancera announces that Professor Carl-Henrik Heldin has been elected to Kancera ́s Board at the company's annual general meeting May 28.
Interim Report for Kancera AB (publ) Q1 2012
Regulatory
January 1 - March 31, 2012 All figures relate to the Kancera Group unless otherwise specified. The 2011 comparison figures for operating income and income after financial items were affected…
Kancera´s ROR inhibitors are active against Fludarabine resistant leukemia
Kancera's inhibitors of ROR1 show an effect on leukemia cells from patients for whom standard therapy is not currently working. Kancera's partner and co-founder Professor Håkan Mellstedt and his research…
A new diagnostic tool increases the value of Kancera´s ROR technology
Kancera has, in collaboration with Professor Håkan Mellstedt's research group at the Karolinska Institute, developed antibodies that permit the development of a diagnostic tool to identify patient response to treatment…
Data indicate broad utility of Kancera’s PFKFB3 inhibitors.
Kancera AB (publ), Sweden, has demonstrated effect with their PFKFB3 inhibitors in cells from three different types of solid tumors. In addition to the previously reported enhancement on effects off…
Kancera presents at Boston seminar April 27th, 2012.
Kancera presents the company and its projects at Cambridge Innovation Center in Boston (MA) USA on Friday April 27th, 2012. The overall topic of the seminar is "Lead Generation and…